enGene Holdings Inc. is a clinical-stage biopharmaceutical company developing genetic medicines for mucosal tissues. Its lead product candidate, detalimogene voraplasmid (formerly EG-70), is being evaluated in the Phase 2 LEGEND trial for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). The company utilizes its proprietary DDX gene delivery platform and plans to file a Biologics License Application with the FDA in the second half of 2026.
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-12-22 | 2025-10-31 | 0001193125-25-328743 | EDGAR | 107K words |
| 2024-12-19 | 2024-10-31 | 0000950170-24-138472 | EDGAR | 122K words |
| 2024-01-29 | 2023-10-31 | 0000950170-24-008125 | EDGAR | 141K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-09-08 | 2026-07-31 | 0001193125-26-384383 | EDGAR | 29K words |
| 2026-03-09 | 2026-01-31 | 0001193125-26-097541 | EDGAR | 24K words |
| 2025-09-11 | 2025-07-31 | 0000950170-25-114224 | EDGAR | 24K words |
| 2025-06-12 | 2025-04-30 | 0000950170-25-085143 | EDGAR | 24K words |
| 2025-03-10 | 2025-01-31 | 0000950170-25-036281 | EDGAR | 22K words |
| 2024-09-10 | 2024-07-31 | 0000950170-24-105180 | EDGAR | 38K words |
| 2024-06-14 | 2024-04-30 | 0000950170-24-073330 | EDGAR | 36K words |
| 2024-03-11 | 2024-01-31 | 0000950170-24-029413 | EDGAR | 33K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-08 | 0001193125-26-384380 | EDGAR | 3K words |
| 2026-08-11 | 0001193125-26-344559 | EDGAR | 3K words |
| 2026-07-17 | 0001193125-26-307795 | EDGAR | 4K words |
| 2026-07-16 | 0001193125-26-305418 | EDGAR | 2K words |
| 2026-03-09 | 0001193125-26-097546 | EDGAR | 26K words |
| 2026-03-09 | 0001193125-26-097534 | EDGAR | 3K words |
| 2026-01-21 | 0001193125-26-017945 | EDGAR | 42K words |
| 2026-01-21 | 0001193125-26-017226 | EDGAR | 2K words |
| 2025-12-22 | 0001193125-25-328706 | EDGAR | 3K words |
| 2025-11-14 | 0001193125-25-283182 | EDGAR | 1K words |
66 total filings indexed. 45 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001980845 |
| Ticker | ENGN |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | Z4 |
| Website | https://www.engene.com |
| Listed | 2023-11-01 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ENGN (~200 tokens, structured JSON with cryptographic provenance)